ID   PARP3_HUMAN             Reviewed;         533 AA.
AC   Q9Y6F1; Q8NER9; Q96CG2; Q9UG81;
DT   26-SEP-2001, integrated into UniProtKB/Swiss-Prot.
DT   03-MAR-2009, sequence version 3.
DT   10-MAY-2017, entry version 166.
DE   RecName: Full=Poly [ADP-ribose] polymerase 3;
DE            Short=PARP-3;
DE            Short=hPARP-3;
DE            EC=2.4.2.30;
DE   AltName: Full=ADP-ribosyltransferase diphtheria toxin-like 3;
DE            Short=ARTD3;
DE   AltName: Full=IRT1;
DE   AltName: Full=NAD(+) ADP-ribosyltransferase 3;
DE            Short=ADPRT-3;
DE   AltName: Full=Poly[ADP-ribose] synthase 3;
DE            Short=pADPRT-3;
GN   Name=PARP3; Synonyms=ADPRT3, ADPRTL3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANT ARG-100.
RA   Koch-Nolte F.;
RL   Submitted (MAR-1998) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ARG-100.
RC   TISSUE=Fetal brain;
RX   PubMed=10329013; DOI=10.1006/geno.1999.5799;
RA   Johansson M.;
RT   "A human poly(ADP-ribose) polymerase gene family (ADPRTL): cDNA
RT   cloning of two novel poly(ADP-ribose) polymerase homologues.";
RL   Genomics 57:442-445(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), VARIANT ARG-100, AND
RP   SUBCELLULAR LOCATION.
RC   TISSUE=Frontal cortex;
RX   PubMed=12640039; DOI=10.1242/jcs.00341;
RA   Augustin A., Spenlehauer C., Dumond H., Menissier-de Murcia J.,
RA   Piel M., Schmit A.-C., Apiou F., Vonesch J.-L., Kock M., Bornens M.,
RA   de Murcia G.M.;
RT   "PARP-3 localizes preferentially to the daughter centriole and
RT   interferes with the G1/S cell cycle progression.";
RL   J. Cell Sci. 116:1551-1562(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R.,
RA   Buhay C.J., Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R.,
RA   Gunaratne P., Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V.,
RA   Hume J., Jackson A., Khan Z.M., Kovar-Smith C., Lewis L.R.,
RA   Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D., Wei S.,
RA   Wheeler D.A., Wright M.W., Worley K.C., Yuan Y., Zhang Z., Adams C.Q.,
RA   Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clendenning J., Clerc-Blankenburg K.P., Chen R., Chen Z., Davis C.,
RA   Delgado O., Dinh H.H., Dong W., Draper H., Ernst S., Fu G.,
RA   Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., Hao B.,
RA   Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., Jackson L.R.,
RA   Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., Liu J.,
RA   Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., Palmeiri A.,
RA   Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J.,
RA   Zhang X., Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H.,
RA   Reinhardt R., Naylor S.L., Yang H., Olson M., Weinstock G.,
RA   Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   ARG-100.
RC   TISSUE=B-cell;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 75-533 (ISOFORM 1), AND
RP   VARIANT ARG-100.
RC   TISSUE=Kidney;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [7]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PRKDC; PARP1;
RP   EZH2; HDAC1; HDAC2; SUZ12; YY1; LRIG3 AND LIG4.
RX   PubMed=16924674; DOI=10.1002/jcb.21051;
RA   Rouleau M., McDonald D., Gagne P., Ouellet M.E., Droit A.,
RA   Hunter J.M., Dutertre S., Prigent C., Hendzel M.J., Poirier G.G.;
RT   "PARP-3 associates with polycomb group bodies and with components of
RT   the DNA damage repair machinery.";
RL   J. Cell. Biochem. 100:385-401(2007).
RN   [8]
RP   NOMENCLATURE.
RX   PubMed=20106667; DOI=10.1016/j.tibs.2009.12.003;
RA   Hottiger M.O., Hassa P.O., Luscher B., Schuler H., Koch-Nolte F.;
RT   "Toward a unified nomenclature for mammalian ADP-
RT   ribosyltransferases.";
RL   Trends Biochem. Sci. 35:208-219(2010).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 178-532 IN COMPLEX WITH THE
RP   INHIBITOR 3-AMINOBENZOIC ACID.
RG   Structural genomics consortium (SGC);
RT   "Human poly(ADP-ribose) polymerase 3, catalytic fragment in complex
RT   with an inhibitor 3-aminobenzoic acid.";
RL   Submitted (APR-2007) to the PDB data bank.
RN   [10]
RP   STRUCTURE BY NMR OF 41-157.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the WGR domain from human poly [ADP-ribose]
RT   polymerase-3.";
RL   Submitted (APR-2008) to the PDB data bank.
CC   -!- FUNCTION: Involved in the base excision repair (BER) pathway, by
CC       catalyzing the poly(ADP-ribosyl)ation of a limited number of
CC       acceptor proteins involved in chromatin architecture and in DNA
CC       metabolism. This modification follows DNA damages and appears as
CC       an obligatory step in a detection/signaling pathway leading to the
CC       reparation of DNA strand breaks. May link the DNA damage
CC       surveillance network to the mitotic fidelity checkpoint.
CC       Negatively influences the G1/S cell cycle progression without
CC       interfering with centrosome duplication. Binds DNA. May be
CC       involved in the regulation of PRC2 and PRC3 complex-dependent gene
CC       silencing. {ECO:0000269|PubMed:16924674}.
CC   -!- CATALYTIC ACTIVITY: NAD(+) + (ADP-D-ribosyl)(n)-acceptor =
CC       nicotinamide + (ADP-D-ribosyl)(n+1)-acceptor.
CC       {ECO:0000255|PROSITE-ProRule:PRU00397}.
CC   -!- SUBUNIT: Interacts with PRKDC and PARP1. Interacts with XRCC5; the
CC       interaction is dependent on nucleic acids. Interacts with XRCC6;
CC       the interaction is dependent on nucleic acids. Interacts with
CC       EZH2, HDAC1, HDAC2, SUZ12, YY1, LRIG3 and LIG4.
CC       {ECO:0000269|PubMed:16924674, ECO:0000269|Ref.9}.
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm, cytoskeleton,
CC       microtubule organizing center, centrosome. Cytoplasm,
CC       cytoskeleton, microtubule organizing center, centrosome,
CC       centriole. Note=Core component of the centrosome. Preferentially
CC       localized to the daughter centriole throughout the cell cycle.
CC       According to PubMed:16924674, it is almost exclusively localized
CC       in the nucleus and appears in numerous small foci and a small
CC       number of larger foci whereas a centrosomal location has not been
CC       detected.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=Short;
CC         IsoId=Q9Y6F1-1; Sequence=Displayed;
CC         Note=More abundant according to PubMed:16924674.;
CC       Name=2; Synonyms=Long;
CC         IsoId=Q9Y6F1-2; Sequence=VSP_007863;
CC   -!- TISSUE SPECIFICITY: Widely expressed; the highest levels are in
CC       the kidney, skeletal muscle, liver, heart and spleen; also
CC       detected in pancreas, lung, placenta, brain, leukocytes, colon,
CC       small intestine, ovary, testis, prostate and thymus.
CC   -!- DOMAIN: According to PubMed:10329013, the N-terminal domain (54
CC       amino acids) of isoform 2 is responsible for its centrosomal
CC       localization. The C-terminal region contains the catalytic domain.
CC   -!- PTM: Auto-poly(ADP)-ribosylation.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y16836; CAC79988.1; -; mRNA.
DR   EMBL; AF083068; AAD29855.1; -; mRNA.
DR   EMBL; AY126341; AAM95460.1; -; mRNA.
DR   EMBL; AC115284; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC014260; AAH14260.1; -; mRNA.
DR   EMBL; AL050034; CAB43246.1; -; mRNA.
DR   CCDS; CCDS43097.1; -. [Q9Y6F1-1]
DR   CCDS; CCDS46839.1; -. [Q9Y6F1-2]
DR   PIR; T08713; T08713.
DR   RefSeq; NP_001003931.3; NM_001003931.3.
DR   RefSeq; NP_005476.4; NM_005485.5.
DR   RefSeq; XP_005264836.2; XM_005264779.4.
DR   RefSeq; XP_016860979.1; XM_017005490.1.
DR   UniGene; Hs.271742; -.
DR   PDB; 2EOC; NMR; -; A=41-157.
DR   PDB; 3C49; X-ray; 2.80 A; A=178-532.
DR   PDB; 3C4H; X-ray; 2.10 A; A=178-532.
DR   PDB; 3CE0; X-ray; 2.80 A; A=178-532.
DR   PDB; 3FHB; X-ray; 2.30 A; A=178-532.
DR   PDB; 4GV0; X-ray; 1.90 A; A=178-532.
DR   PDB; 4GV2; X-ray; 1.80 A; A=178-532.
DR   PDB; 4GV4; X-ray; 1.80 A; A=178-532.
DR   PDB; 4L6Z; X-ray; 2.00 A; A=178-532.
DR   PDB; 4L70; X-ray; 2.00 A; A=178-532.
DR   PDB; 4L7L; X-ray; 2.10 A; A=178-532.
DR   PDB; 4L7N; X-ray; 1.80 A; A=178-532.
DR   PDB; 4L7O; X-ray; 2.00 A; A=178-532.
DR   PDB; 4L7P; X-ray; 2.30 A; A=178-532.
DR   PDB; 4L7R; X-ray; 2.20 A; A=178-532.
DR   PDB; 4L7U; X-ray; 2.80 A; A=178-532.
DR   PDBsum; 2EOC; -.
DR   PDBsum; 3C49; -.
DR   PDBsum; 3C4H; -.
DR   PDBsum; 3CE0; -.
DR   PDBsum; 3FHB; -.
DR   PDBsum; 4GV0; -.
DR   PDBsum; 4GV2; -.
DR   PDBsum; 4GV4; -.
DR   PDBsum; 4L6Z; -.
DR   PDBsum; 4L70; -.
DR   PDBsum; 4L7L; -.
DR   PDBsum; 4L7N; -.
DR   PDBsum; 4L7O; -.
DR   PDBsum; 4L7P; -.
DR   PDBsum; 4L7R; -.
DR   PDBsum; 4L7U; -.
DR   ProteinModelPortal; Q9Y6F1; -.
DR   SMR; Q9Y6F1; -.
DR   BioGrid; 115351; 8.
DR   STRING; 9606.ENSP00000381740; -.
DR   BindingDB; Q9Y6F1; -.
DR   ChEMBL; CHEMBL5083; -.
DR   DrugBank; DB09074; Olaparib.
DR   GuidetoPHARMACOLOGY; 2864; -.
DR   iPTMnet; Q9Y6F1; -.
DR   PhosphoSitePlus; Q9Y6F1; -.
DR   BioMuta; PARP3; -.
DR   DMDM; 224471880; -.
DR   PaxDb; Q9Y6F1; -.
DR   PeptideAtlas; Q9Y6F1; -.
DR   PRIDE; Q9Y6F1; -.
DR   DNASU; 10039; -.
DR   Ensembl; ENST00000398755; ENSP00000381740; ENSG00000041880.
DR   GeneID; 10039; -.
DR   KEGG; hsa:10039; -.
DR   UCSC; uc003dbz.4; human. [Q9Y6F1-1]
DR   CTD; 10039; -.
DR   DisGeNET; 10039; -.
DR   GeneCards; PARP3; -.
DR   HGNC; HGNC:273; PARP3.
DR   HPA; HPA067657; -.
DR   MIM; 607726; gene.
DR   neXtProt; NX_Q9Y6F1; -.
DR   PharmGKB; PA24593; -.
DR   eggNOG; KOG1037; Eukaryota.
DR   eggNOG; ENOG410XP18; LUCA.
DR   HOGENOM; HOG000173055; -.
DR   HOVERGEN; HBG053514; -.
DR   InParanoid; Q9Y6F1; -.
DR   KO; K10798; -.
DR   OrthoDB; EOG091G06SC; -.
DR   PhylomeDB; Q9Y6F1; -.
DR   TreeFam; TF315407; -.
DR   BRENDA; 2.4.2.30; 2681.
DR   SignaLink; Q9Y6F1; -.
DR   EvolutionaryTrace; Q9Y6F1; -.
DR   GeneWiki; PARP3; -.
DR   GenomeRNAi; 10039; -.
DR   PRO; PR:Q9Y6F1; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000041880; -.
DR   CleanEx; HS_PARP3; -.
DR   ExpressionAtlas; Q9Y6F1; baseline and differential.
DR   Genevisible; Q9Y6F1; HS.
DR   GO; GO:0005814; C:centriole; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0035861; C:site of double-strand break; IDA:MGI.
DR   GO; GO:0003824; F:catalytic activity; TAS:ProtInc.
DR   GO; GO:0003910; F:DNA ligase (ATP) activity; IBA:GO_Central.
DR   GO; GO:0003950; F:NAD+ ADP-ribosyltransferase activity; IDA:MGI.
DR   GO; GO:0051103; P:DNA ligation involved in DNA repair; IBA:GO_Central.
DR   GO; GO:0006281; P:DNA repair; TAS:ProtInc.
DR   GO; GO:0006302; P:double-strand break repair; IDA:MGI.
DR   GO; GO:0006273; P:lagging strand elongation; IBA:GO_Central.
DR   GO; GO:0051106; P:positive regulation of DNA ligation; IGI:MGI.
DR   GO; GO:0006471; P:protein ADP-ribosylation; IDA:MGI.
DR   GO; GO:1990166; P:protein localization to site of double-strand break; IMP:MGI.
DR   GO; GO:0060236; P:regulation of mitotic spindle organization; IMP:MGI.
DR   GO; GO:0000723; P:telomere maintenance; IMP:MGI.
DR   Gene3D; 1.20.142.10; -; 1.
DR   Gene3D; 2.20.140.10; -; 1.
DR   InterPro; IPR031275; PARP3.
DR   InterPro; IPR012317; Poly(ADP-ribose)pol_cat_dom.
DR   InterPro; IPR004102; Poly(ADP-ribose)pol_reg_dom.
DR   InterPro; IPR008893; WGR_domain.
DR   PANTHER; PTHR10459:SF81; PTHR10459:SF81; 1.
DR   Pfam; PF00644; PARP; 1.
DR   Pfam; PF02877; PARP_reg; 1.
DR   Pfam; PF05406; WGR; 1.
DR   SMART; SM00773; WGR; 1.
DR   SUPFAM; SSF142921; SSF142921; 1.
DR   SUPFAM; SSF47587; SSF47587; 1.
DR   PROSITE; PS51060; PARP_ALPHA_HD; 1.
DR   PROSITE; PS51059; PARP_CATALYTIC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Cytoplasm;
KW   Cytoskeleton; Glycosyltransferase; NAD; Nucleus; Polymorphism;
KW   Reference proteome; Transferase.
FT   CHAIN         1    533       Poly [ADP-ribose] polymerase 3.
FT                                /FTId=PRO_0000211329.
FT   DOMAIN      182    300       PARP alpha-helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00398}.
FT   DOMAIN      313    533       PARP catalytic. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00397}.
FT   MOTIF        14     20       Nuclear localization signal.
FT                                {ECO:0000255}.
FT   VAR_SEQ       1      1       M -> MSLLFLAM (in isoform 2).
FT                                {ECO:0000303|PubMed:12640039,
FT                                ECO:0000303|Ref.1}.
FT                                /FTId=VSP_007863.
FT   VARIANT      91     91       S -> N (in dbSNP:rs34224216).
FT                                /FTId=VAR_056643.
FT   VARIANT     100    100       H -> R (in dbSNP:rs28547534).
FT                                {ECO:0000269|PubMed:10329013,
FT                                ECO:0000269|PubMed:12640039,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:17974005,
FT                                ECO:0000269|Ref.1}.
FT                                /FTId=VAR_054622.
FT   VARIANT     269    269       Q -> R (in dbSNP:rs323870).
FT                                /FTId=VAR_056644.
FT   CONFLICT     80     80       N -> K (in Ref. 2; AAD29855).
FT                                {ECO:0000305}.
FT   CONFLICT    171    171       G -> A (in Ref. 2; AAD29855).
FT                                {ECO:0000305}.
FT   CONFLICT    411    411       K -> E (in Ref. 6; CAB43246).
FT                                {ECO:0000305}.
FT   STRAND       50     53       {ECO:0000244|PDB:2EOC}.
FT   TURN         54     56       {ECO:0000244|PDB:2EOC}.
FT   STRAND       61     74       {ECO:0000244|PDB:2EOC}.
FT   TURN         75     78       {ECO:0000244|PDB:2EOC}.
FT   STRAND       79     89       {ECO:0000244|PDB:2EOC}.
FT   STRAND       95    100       {ECO:0000244|PDB:2EOC}.
FT   STRAND      111    117       {ECO:0000244|PDB:2EOC}.
FT   HELIX       118    133       {ECO:0000244|PDB:2EOC}.
FT   HELIX       140    142       {ECO:0000244|PDB:2EOC}.
FT   STRAND      147    149       {ECO:0000244|PDB:2EOC}.
FT   STRAND      151    153       {ECO:0000244|PDB:2EOC}.
FT   HELIX       187    196       {ECO:0000244|PDB:4GV2}.
FT   HELIX       199    208       {ECO:0000244|PDB:4GV2}.
FT   TURN        213    215       {ECO:0000244|PDB:4GV2}.
FT   TURN        218    220       {ECO:0000244|PDB:4GV2}.
FT   HELIX       223    240       {ECO:0000244|PDB:4GV2}.
FT   STRAND      246    248       {ECO:0000244|PDB:3C49}.
FT   HELIX       250    260       {ECO:0000244|PDB:4GV2}.
FT   STRAND      265    268       {ECO:0000244|PDB:3C49}.
FT   HELIX       276    298       {ECO:0000244|PDB:4GV2}.
FT   HELIX       303    307       {ECO:0000244|PDB:4GV2}.
FT   STRAND      309    311       {ECO:0000244|PDB:4GV2}.
FT   HELIX       314    321       {ECO:0000244|PDB:4GV2}.
FT   STRAND      325    328       {ECO:0000244|PDB:4GV2}.
FT   HELIX       336    346       {ECO:0000244|PDB:4GV2}.
FT   STRAND      349    351       {ECO:0000244|PDB:4GV2}.
FT   STRAND      354    362       {ECO:0000244|PDB:4GV2}.
FT   TURN        364    366       {ECO:0000244|PDB:3C49}.
FT   HELIX       367    371       {ECO:0000244|PDB:4GV2}.
FT   TURN        372    375       {ECO:0000244|PDB:4GV2}.
FT   STRAND      379    385       {ECO:0000244|PDB:4GV2}.
FT   HELIX       388    390       {ECO:0000244|PDB:4GV2}.
FT   HELIX       391    397       {ECO:0000244|PDB:4GV2}.
FT   STRAND      411    418       {ECO:0000244|PDB:4GV2}.
FT   HELIX       419    423       {ECO:0000244|PDB:4GV2}.
FT   STRAND      429    431       {ECO:0000244|PDB:4GV2}.
FT   STRAND      434    445       {ECO:0000244|PDB:4GV2}.
FT   STRAND      448    454       {ECO:0000244|PDB:4GV2}.
FT   STRAND      467    471       {ECO:0000244|PDB:4GV2}.
FT   STRAND      473    477       {ECO:0000244|PDB:4GV2}.
FT   HELIX       479    481       {ECO:0000244|PDB:4GV2}.
FT   STRAND      483    487       {ECO:0000244|PDB:4GV2}.
FT   STRAND      490    494       {ECO:0000244|PDB:4GV2}.
FT   STRAND      499    501       {ECO:0000244|PDB:4GV2}.
FT   HELIX       503    505       {ECO:0000244|PDB:4GV2}.
FT   STRAND      509    512       {ECO:0000244|PDB:4GV2}.
FT   STRAND      514    519       {ECO:0000244|PDB:4GV2}.
FT   HELIX       520    522       {ECO:0000244|PDB:4GV2}.
FT   STRAND      523    532       {ECO:0000244|PDB:4GV2}.
SQ   SEQUENCE   533 AA;  60070 MW;  BF728C3D88722029 CRC64;
     MAPKPKPWVQ TEGPEKKKGR QAGREEDPFR STAEALKAIP AEKRIIRVDP TCPLSSNPGT
     QVYEDYNCTL NQTNIENNNN KFYIIQLLQD SNRFFTCWNH WGRVGEVGQS KINHFTRLED
     AKKDFEKKFR EKTKNNWAER DHFVSHPGKY TLIEVQAEDE AQEAVVKVDR GPVRTVTKRV
     QPCSLDPATQ KLITNIFSKE MFKNTMALMD LDVKKMPLGK LSKQQIARGF EALEALEEAL
     KGPTDGGQSL EELSSHFYTV IPHNFGHSQP PPINSPELLQ AKKDMLLVLA DIELAQALQA
     VSEQEKTVEE VPHPLDRDYQ LLKCQLQLLD SGAPEYKVIQ TYLEQTGSNH RCPTLQHIWK
     VNQEGEEDRF QAHSKLGNRK LLWHGTNMAV VAAILTSGLR IMPHSGGRVG KGIYFASENS
     KSAGYVIGMK CGAHHVGYMF LGEVALGREH HINTDNPSLK SPPPGFDSVI ARGHTEPDPT
     QDTELELDGQ QVVVPQGQPV PCPEFSSSTF SQSEYLIYQE SQCRLRYLLE VHL
//
